Overview

Quarterly results are the window made available to the general public to understand the company's performance. A quarterly earnings report is a key way to tell current and potential investors how it is positioned financially. In this context, Finglobedirect, which has been providing company and financial information globally since two decades, brings out an analytical report - Japanese Life Sciences 300: Analysis of Quarterly Earnings (ending September 30, 2015).

Research Objective

The objective of this report is to provide the global investors with a complete resourceful analytical report for familiarizing with the financial position of the leading Japanese life science companies at the end of the quarter ending September 2015, which they would find beneficial to pursue for making business decisions in this sector.

Research Sources

Our research team has compiled financial information of Japanese life science companies from reliable primary and secondary sources including company websites, press releases, and stock exchanges.

• Comprehensive focus on financial performance of Japanese life science companies for the latest two quarters
• Presents composite rankings of leading Japanese life science companies by various categories
• Presents rankings for the leading Japanese life science companies by various attributes such as growth, profitability, asset turnover, market valuation and deciles
• Provides averages of key variable ratios for companies grouped under various modules such as market capitalization, industries, and key attributes
• Provides at one glance the listing of Japanese life science companies covered along with values of key variables

• 1.1 Overall composite rankings
• 1.2 Composite rankings: By industry
• 1.3 Composite rankings: By market capitalization group
• 1.4 Composite rankings: By R & D focus
• 1.5 Composite rankings: By foreign sales focus

• 2.1 Top 100 fastest growing companies
• 2.2 Top 100 most profitable companies
• 2.3 Top 100 most asset turnover companies
• 2.4 Top 100 highest market valuation companies
• 2.5 Top 100 companies based on deciles rankings

• 3.1 Market capitalization group
• 3.2 Industries
• 3.3 Key attributes

The following methodology has been adopted for computing composite rankings as well as rankings by various attributes:

Composite Rankings

• Financial variables such as Total Sales, Net Income, Total Assets, and Total Equity have been considered to compute composite rankings.
• Values of these variables for last two quarters, where available, have been added to calculate semi-annual data so that comparison with other companies not providing quarterly data becomes possible. Values have been extracted from company quarterly reports or semi-annual reports.
• Values for all four variables must be available to rank companies.
• All values are having varied currency and units and thus have been converted into millions of USD by a separate program module.
• Those companies with Net Income values of more than 75% of Total Sales are excluded as such companies are development companies with royalty or interest income.
• Also those companies with Total Sales value of less than USD 10 million have been excluded.
• Each of the variables has been ranked individually based on values (higher is better) for latest two quarter equivalent period.
• Average of individual ranks for each quarter has been calculated to generate deciles.
• Deciles are then used to provide composite rank for companies.

Growth Rankings

• Total Sales growth and Total Assets growth are considered to compute growth rank of the company for latest quarter vs. previous quarter and previous quarter vs. previous to previous quarter.
• Deciles have been computed based on growth ranks for two key financials.
• Deciles for both periods are then used to provide growth rank for companies.

Profitability Rankings

• Key profitability ratios such as Net Income to Total Sales, Net Income to Total Assets and Net Income to Total Equity have been computed for assigning profitability ranks.
• Individual ranks have been assigned to all three ratios for latest two quarters and average of ranks for each quarter is used to compute deciles.
• Deciles for both quarters are then used to provide profitability rank for companies.
• Negative net income values are also considered for rankings.

Asset Turnover Rankings

• Total Sales to Total Assets and Total Sales to Total Equity have been computed for assigning asset turnover ranks.
• Individual ranks have been assigned to both the ratios for latest two quarters and average of ranks for each quarter is used to compute deciles.
• Deciles for both quarters are then used to provide asset turnover rank for companies.

Market Valuation Rankings

• Key market valuation ratios such as Market Cap to Total Sales, Market Cap to Net Income, and Market Cap to Total Equity have been computed for assigning market valuation ranks. Sales and net income denomination issue has been taken into account while computing Market Cap to Total Sales and Market Cap to Net Income ratios.
• Individual ranks have been assigned to all three ratios for the latest quarter and average of ranks for the quarter is used to compute deciles.
• Deciles for both quarters are then used to provide market valuation rank for companies.

Deciles Rankings

• Deciles rankings are computed based on 4 different sectional ranks – Growth rank, Profitability rank, Asset Turnover rank and Market Valuation rank.
• Each section is ranked individually for latest two periods and average of rank values is used to compute deciles.
• Later deciles values over rank of 4 sectional ranks are used to assign deciles rankings.

The list of leading 300 Japanese life science companies covered in this analytical report is mentioned below:

Forthcoming...

• Analysis of most recent quarterly earnings provided through this analytical report
• Analysts with years of experience analyze the quarterly financial data for the leading Japanese life science companies
• Financial information comprehensively compiled from reliable primary and secondary sources
• Useful for global investors to get a better understanding of where the leading Japanese life science companies stand

Research Report Japan Life Sciences 300: Analysis of Quarterly Earnings (ending September 30, 2015): $400

Select Product Japan Life Sciences 300: Analysis of Quarterly Earnings (ending September 30, 2015)

Select Price $400

$850 for all three publications: Japan Life Sciences series on Analysis/Investors Presentations (savings of $245)

• Japan Life Sciences Business 300: Recent Growth and New Directions $500
• Japan Life Sciences 300: Analysis of Quarterly Earnings (ending September 30, 2015) $400
• Japan Life Sciences 300: Investor Presentations( 25 companies) $195

Select Product Japan Life Sciences Analysis series: 3 products

Select Price $850

Please send us an email for any further queries to info@finglobedirect.com.